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Abstract Recently, a novel cytokine, cardiotrophin-1 (CT-I), 
was cloned and found to induce cardiac myocyte hypertrophy in 
vitro. Amino acid sequence similarity showed CT-1 to be a mem- 
ber of the IL-6/LIF/CNTFIOSM/IL-11 cytokine family. Since 
all known members of the IL-6 cytokine family induce an hepatic 
acute phase protein (APP) gene expression, we investigated the 
ability of CT-I to induce a liver acute phase response. Upon 
stimulation of rat hepatoma cells, CT-1 and LIF induced the 
strongest rat fibrinogen mRNA expression, OSM and IL-6 in- 
duced a less pronounced response. When human hepatoma cells 
and primary rat hepatocytes were stimulated with CT-1, the 
expression of human haptoglobin and rat ot2-macrogiobulin 
mRNA was induced. The induction of the acute phase response 
was dose- and time-dependent. In this study we demonstrate that 
CT-1, a novel cytokine belonging to the IL-6 cytokine family, is 
a hepatocyte stimulating factor. 
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mon signaling subunit, gp130 [9,10]. Some members of the IL-6 
cytokine family (IL-6 and IL-11) [11,12] induce the homodimer- 
ization of gp130, while others (LIF, OSM; and CNTF) induce 
the heterodimerization of gp 130 and of the 190 kDa LIF recep- 
tor [13,14]. Following dimerization of the signaling compo- 
nents, these receptors induce a number of intracellular signaling 
events including activation of the transcription factor NF-IL-6 
and activiation of the Jak/STAT signaling pathway [15]. 
Cardiotrophin- 1 is a novel cytokine that induces cardiac my- 
ocyte hypertrophy in vitro [16]. It has been demonstrated that 
CT-1 leads to a heterodimerization of gp 130 and the LIF recep- 
tor [17]. Based on the fact that CT-1 seems to be a member of 
the IL-6 cytokine family [16] and acts via the LIF receptor/ 
gpl30 heterodimer, we asked the question, whether CT-1 is a 
hepatocyte stimulating factor. In this study, we show that CT-I 
regulates acute phase protein expression in human and rat 
hepatoma cells as well as in primary rat hepatocytes. The extent 
of stimulation by CT-1 is comparable to the one obtained with 
LIF. 
I. Introduction 
Inflammation, tissue injuries, neoplastic cell growth, and im- 
munological disorders are characterized by marked alterations 
in plasma levels of a number of liver-derived proteins called 
acute phase proteins (APPs). The induction of this hepatocyte 
response is mediated primarily through soluble cytokines that 
interact with specific receptors on the surface of hepatocytes to
induce the expression of genes for APP [1]. IL-6 seems to be 
the major inducer of APP response in vivo although it has been 
shown that other members of this cytokine family exhibit hepa- 
tocyte stimulating activities in vitro. Members of the inter- 
leukin-6 family are interleukin-6 (IL-6) [2,3], leukemia inhib- 
itory factor (LIF) [4,5], oncostatin M (OSM) [6], interleukin-11 
(IL-11) [7], and ciliary neurotrophic factor (CNTF) [8]. 
This cytokine family acts on target cells via specific ell sur- 
face receptors generally consisting of different subunits for 
ligand binding and signal transduction. The IL-6 receptor fam- 
ily is composed of multisubunit complexes that share a corn- 
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2. Materials and methods 
2.1. Materials 
Human haptoglobin cDNA was a gift of Dr. D. Samols (Cleveland, 
OH, USA), rat fl-fibrinogen cDNA was supplied by Dr. A. Mitchell, 
Parkville, Australia. Recombinant human (rh) IL-6 was prepared as 
described [18]. Oncostatin M and leukemia inhibitory factor (LIF) were 
obtained from Dr. J. Brakenhoff, CLB, Amsterdam, NL. CT-1 was 
prepared as recently described [16]. Soluble human IL-6 receptor (shIL- 
6R) was expressed as described [19]. [a-3ZP]dA'l'P (l 10 YBq/mmol) was 
from Amersham International (Amersham, UK). 
2.2. Cell culture 
Human hepatoma cells (HepG2 cells, HepG2-IL-6 cells [19]), rat 
hepatoma cells (Fao cells) were grown in DMEM at 5% COz in a 
water-saturated atmosphere. All cell culture media were supplemented 
with 10% FCS, 100 mg/l streptomycin, and 60 mg/1 penicillin. Primary 
rat hepatocytes from male Sprague-Dawley rats were isolated as de- 
scribed [20,21] and cultivated for 48 h prior to cytokine stimulation. 
2.3. Extraction of total RNA and Northern (RNA) blot analyis 
Total RNA was prepared from cells using the phenol extraction 
method [22]. 10/lg of heat-denatured RNA per sample was fractionated 
on a 1% agarose gel with 7% formaldehyde. The separated RNA was 
transferred to GenScreen Plus membranes (Dupont-New England Nu- 
clear, Dreieich, Germany) according to the manufacturers instructions. 
The filters were prehybridized at 68°C for 2h in 10% dextran sulfate, 
1 M NaCI, 1% SDS, and hybridized in the same solution with 32p. 
labeled cDNA fragments by random priming [23]. The following probes 
were used: 0.9-kB Hinfll restriction fragment of human Haptoglobin 
cDNA, 0.66-kB PstI fragment of rat ~2_macroglobulin, a d a 0.7-kB 
EcoRI fragment of rat fl-fibrinogen. Photographs ofthe ethidium bro- 
mide stained gels were used to ensure qual oading of the RNA gels 
(data not shown). 
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Fig. l. Effects of CT-1, LIF, OSM, and IL-6 on acute-phase protein 
expression i Fao cells. Following incubation of the cells with 20 ng/ml 
CT-I, 50 ng/ml LIF, 50 ng/ml OSM, and 10 ng/ml IL-6 for 18 h, total 
RNA was prepared and subjected to Northern blot analysis. The filters 
were hybridized with a 32p-labeled cDNA coding for rat fl-fibrinogen. 
3. Results and discussion 
To examine whether CT-I exhibits hepatocyte stimulating 
activity, we incubated HepG2 cells and Fao cells for 18 h in the 
presence of CT-1. For comparison, cells were incubated with 
LIF, OSM, and IL-6, which are well-documented hepatocyte- 
stimulating factors [2-4,24,25]. 
Fig. 1 shows the stimulation of mRNA expression of the 
acute phase protein fl-fibrinogen in Fao cells: incubation with 
LIF and CT-1 gave the strongest stimulation of fl-fibrinogen 
mRNA, incubation with OSM and IL-6 led to a less marked 
induction of acute phase proteins. 
Time course experiments were carried out incubating Fao 
cells with CT-1 and IL-6 (Fig. 2A). Upon stimulation with 
CT- 1, there was a full induction offl-fibrinogen expression after 
2 h which was only slightly increased when incubation periods 
were extended to 18 h. To further confirm this experiment, Fao 
cells were incubated for 20 min, 40 min, and one hour with the 
same dose of CT-1. A full induction offl-fibrinogen was seen 
after 40 rain (data not shown). Following stimulation with IL-6, 
maximal induction of fl-fibrinogen was seen after 18h. Figure 
2B shows dose-response experiments demonstrating that max- 
imal fl-fibrinogen induction after stimulation with CT-1 was 
seen at a concentration of 20 ng/ml. 
Fig. 3A shows the stimulation of mRNA expression of the 
acute phase protein haptoglobin i HepG2 cells: while IL-6 and 
OSM treatment led to the strongest stimulation, CT-1 and LIF 
induced acute phase protein synthesis to a comparable and less 
pronounced extent. Fig. 3B demonstrates a imilar experiment 
with HepG2-IL-6 cells [19] which are stably transfected with the 
human IL-6 cDNA, do not express gp80 1L-6 receptors on their 
surface and have lost their responsiveness to IL-6 but not to 
other cytokines uch as LIF or TGF-fl. It can be seen from the 
figure that incubation of these cells with CT-1 and LIF, but not 
with IL-6, showed an equally strong induction of haptoglobin 
mRNA expression. We conclude that the IL-6R is not required 
for CT-1 activity. The different extent of acute phase protein 
mRNA induction found in Fao cells and HepG2 cells stimu- 
lated with either CT-1 and LIF or with IL-6 and OSM which 
is demonstrated in Figs. 1 and 3, is most likely due to different 
relative xpression levels of LIF receptor (primary receptor for 
CT-1 and LIF) or gpl30 (primary receptor for OSM, signal 
transducer for IL-6). 
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As shown in Fig. 4, primary rat hepatocytes were stimulated 
with CT-1, IL-6, LIF, and OSM. The stimulation of the acute 
phase protein (x2M was most pronounced upon the incubation 
with IL-6. Incubation with CT-1, LIF, and OSM led to a very 
weak response, being only slightly stronger than the control. 
An explanation for this finding could be that the primary rat 
hepatocytes u ed in this experiment expressed much lower lev- 
els of LIF receptor than gpl30 on their surface. As a conse- 
quence, these hepatocytes are more sensitive to IL-6 which only 
needs gpl30 for signaling, compared to CT-I, OSM, and L1F, 
which require a heterodimer of LIF recpetor and gpl30 for 
signal transduction. 
Interestingly, Pennica et al. [16] have shown that CT-1 
mRNA was detected in various mouse tissues including liver 
raising the possibility of an autocrine loop in the regulation of 
CT-1 expression. However, we failed to demonstrate CT-I 
mRNA in unstimulated and CT-1 stimulated HepG2 cells or 
primary rat hepatocytes (data not shown). These findings may 
argue against an involvement of an autocrine loop in CT-1 
regulation and may also be an indication that CT- 1 is expressed 
in liver cells other than hepatocytes, uch as Kupffer cells. 
In this study we demonstrate hat the newly discovered cy- 
tokine CT-1 which seems to belong to the IL-6 cytokine family 
is a hepatocyte stimulating factor. In vitro experiments have 
demonstrated that the known members of the IL-6 cytokine 
family display overlapping activities on target cells. This func- 
tional redundancy among members of this family may be 
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Fig. 2. Time course and dose-response of rat fl-fibrinogen induction of 
Fao cells in response to CT-1. (A) For the time course xperiment, cells 
were stimulated with 20 ng/ml CT-1 and with 10 ng/ml IL-6 for the 
times indicated. (B) For the dose-response experiments, cells were 
stimulated for 18 h with various dosages as indicated inthe figure. Total 
RNA was prepared and subjected to Northern blot analysis. The filters 
were hybridized with a 32p-labeled cDNA coding for rat fl-fibrinogen. 
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~aused by interactions of specific binding receptors with the 
, 'ommon signal transducing molecule gpl30. The importance 
,,f this functional redundancy is supported by the fact that IL-6 
knock-out mice are still able to elicit an acute phase protein 
~xpression upon LPS stimulation [26]. It is still unknown which 
,ytokines besides IL-6 induce the acute phase protein expres- 
ion  in vivo. Given the fact that certain receptor subunits are 
hared by different cytokines of the IL-6 family, our finding 
hat CT- 1 is a hepatocyte stimulating factor highlights the con- 
'ept of functional redundancy. There might be the possibility 
hat CT-1 represents a candidate which could be a supplement 
o cytokines like IL-6 in various inflammatory states. 
It is noteworthy that the time course experiment of the induc- 
ion of fl-fibrinogen expression by CT-1 is different from the 
)he obtained with IL-6. We currently have no explanation for 
hese discrepancies but it will be interesting to compare primary 
"eceptor events between the two cytokines. 
Although CT-1 was isolated based on its ability to induce 
:ardiac myocyte hypertrophy [16,17], it has a much wider spec- 
trum of activities as found for all other members of the IL-6 
t'amily [1]. Future studies will be needed to define the specific 
role of CT-1 within the family of IL-6-type cytokines. 
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Fig. 3. Effects of CT-1, LIF, OSM, and IL-6 on acute-phase protein 
expression in (A) human hepatoma HepG2 cells and (B) HepG2-IL-6 
cells. Following incubation of cells with 20 ng/rnl CT-1, 50 ng/ml LIF, 
50 ng/ml OSM, 10 ng/ml IL-6, and 100 ng/ml gpS0/IL-6R for 18 h, total 
RNA was prepared und subjected to Northern blot analysis. The filters 
were hybridized with a 32p-labeled cDNA coding for human haptog- 
lobin, gp80/IL-6R, soluble form of the ligand binding subunit of the 
IL-6 receptor complex. 
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Fig. 4. Effects of CT-I, LIF, OSM, and 1L-6 on acute-phase protein 
expression in primary rat hepatocytes cells. Following incubation of 
cells with 20 ng/ml CT-1, 10 ng/ml LIF, 20 ng/ml OSM, and 10 ng/ml 
IL-6 for 18 h, total RNA was prepared und subjected to Northern blot 
analysis. The filters were hybridized with a 32p-labeled cDNA coding 
for rat ct2-macroglobulin. 
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